


## YSR734

<b>Cat. No.:</b>	HY-161050		
<b>CAS No.:</b>	3032969-58-4		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>23</sub> F <sub>5</sub> N <sub>4</sub> O <sub>5</sub> S		
<b>Molecular Weight:</b>	598.54		
<b>Target:</b>	HDAC; Apoptosis		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (167.07 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	1.6707 mL	8.3537 mL	16.7073 mL
5 mM		0.3341 mL	1.6707 mL	3.3415 mL	
	10 mM	0.1671 mL	0.8354 mL	1.6707 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (8.35 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	YSR734 (Compound 21) is a covalent HDAC inhibitor with IC <sub>50</sub> values of 110 nM, 154 nM, and 143 nM for HDAC1, HDAC2, and HDAC3, respectively. YSR734 can induce apoptosis in leukemia cells. YSR734 can induce myoblast differentiation and is used in the study of Duchenne muscular dystrophy <sup>[1]</sup> .
--------------------	--

### REFERENCES

[1]. Raouf YS, et al. Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy. J Med Chem. 2023 Dec 28;66(24):16658-16679.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA